
    
      This is a phase I, prospective, randomized, open-label, two-center study. A total 60 healthy
      volunteers will be screened for baseline characteristic inclusion/exclusion criteria after
      providing a written informed consent. Eligible subjects will be recruited and equally
      randomized to either receive 2 doses of EV71 vaccine 0.25ml or 0.5ml. All subjects should be
      followed till Day 210.
    
  